# Elcatonin

> Elcatonin is a synthetic analog of eel calcitonin, chemically modified from the natural eel hormone to improve stability. It is used in Japan and some other Asian markets for osteoporosis and associated bone pain, though it does not hold FDA approval and is not marketed in the United States. As a calcitonin-class peptide, it works by inhibiting bone resorption to help slow bone loss. It is administered by intramuscular injection under medical supervision.

- URL: https://www.lifeconverted.com/peptides/elcatonin
- Primary category: Other & Clinical
- Effectiveness rank: #23 in Other & Clinical
- Evidence level: Well studied
- Route: Intramuscular (Administered by intramuscular injection; not available as an approved product in the United States.)
- Dose range: 10-40 IU
- Dose tiers: low 10 IU; moderate 20 IU; high 40 IU
- Half-life: Very short plasma half-life, on the order of minutes to under an hour, though biological effects on bone turnover last considerably longer
- Timing: As directed by your clinician
- Cycle: Continuous weekly or twice-weekly intramuscular injections during active osteoporosis treatment on, Reassessed periodically with bone mineral density monitoring; not typically stopped abruptly off (Primarily used in Japan and parts of Asia; not an FDA-approved product in the United States.)
- Storage: Refrigerate at 2-8°C, protected from light; do not freeze.

## Mechanism of action

Elcatonin binds calcitonin receptors on osteoclasts, the cells responsible for breaking down bone tissue, directly inhibiting their activity and reducing bone resorption. This shifts the balance of bone remodeling toward reduced turnover, which can help preserve bone mineral density over time. Calcitonin receptor activation in the central nervous system may also contribute to its reported analgesic effect on bone-related pain.

## Reported benefits

- Inhibits osteoclast-mediated bone resorption
- May reduce bone pain associated with osteoporosis or vertebral compression
- Used as an option for patients unable to tolerate bisphosphonates
- Long track record of use in Japan for osteoporosis management

## Reported side effects

- Nausea and gastrointestinal discomfort
- Flushing and facial warmth
- Injection site reactions
- Rare hypersensitivity reactions

## Common protocols

- Weekly or twice-weekly intramuscular elcatonin for osteoporosis-related bone pain and resorption control (Japan and other Asian markets)

## Stacking notes

Commonly combined with calcium and vitamin D supplementation; not typically combined with other calcitonin products or bisphosphonates without specialist guidance.

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer